Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 2, 2012, Pages 181-184

  Atay, Julie K ^a   Fiumara, Karen ^a   Piazza, Gregory ^a   Fanikos, John ^a   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

atrial fibrillation; dabigatran; venous thromboembolism; warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG COST; HEART ATRIUM FIBRILLATION; HOSPITAL FINANCE; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BOSTON; BUDGETS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; HOSPITAL COSTS; HOSPITALS, UNIVERSITY; HUMANS; INTERNATIONAL NORMALIZED RATIO; LABORATORIES, HOSPITAL; PERSONNEL, HOSPITAL; QUALITY-ADJUSTED LIFE YEARS; SALARIES AND FRINGE BENEFITS; STROKE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84858424207     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611416642     Document Type: Article

References (18)

1. Garcia D, Libby E, Crowther MA.. The new oral anticoagulants. Blood. 2010 ; 115 (1). 15-20
2. Ma TK, Yan BP, Lam YY.. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther. 2011 ; 129 (2). 185-194
3. Eriksson BI, Quinlan DJ, Weitz JI.. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009 ; 48 (1). 1-22
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (27). 1139-1151
5. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361 (24). 2342-2352
6. Eikelboom JE, Weitz JI.. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost. 2009 ; 101 (1). 2-4
7. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 ; 376 (9745). 975-983
8. Bjorholt I, Andersson S, Nilsson GH, Krakau I.. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract. 2007 ; 8: 6
9. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 ; 154 (1). 1-11
10. Owens DK.. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998 ; 13 (6). 716-717 (Pubitemid 28473801)
11. Schwartz NE, Albers GW.. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke. 2010 ; 41 (6). 1307-1309
12. Davidson BL, Sullivan SD, Kahn SR, et al. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 ; 124 (5). 393S - 396S (Pubitemid 38005467)
13. Sorensen SV, Dewilde S, Singer DE, Borris L, Bossuyt P, Raskob G.. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J. 2009 ; 157 (6). 1064-1073
14. Hankey GJ, Eikelboom JW.. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010 ; 9 (3). 273-284
15. Luengo-Fernandez R, Gray AM, Rothwell PM.. Costs of stroke using patient-level data: a critical review of the literature. Stroke. 2009 ; 40 (2). e18 - e23
16. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF.. Lifetime cost of stroke in the United States. Stroke. 1996 ; 27 (9). 1459-1466 (Pubitemid 26295889)
17. Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L.. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm. 2005 ; 11 (8). 663-673
18. Stangier J, Rathgen K, Stähle H, Mazur D.. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010 ; 49 (4). 259-268